Lucid Capital Markets Double Downgrades Quince Therapeutics Inc. (QNCX) to Sell, Target to $0
Tweet Send to a Friend
Lucid Capital Markets analyst Elemer Piros downgraded Quince Therapeutics Inc. (NASDAQ: QNCX) from Buy to Sell (from $8.00).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
